Please provide your email address to receive an email when new articles are posted on . The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W.

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

The Sentinel cerebral protection system (Boston Scientific) was infrequently used during TAVI procedures performed in Germany over a recent 3-year span, and it was not associated with less clinical ...

CAESAREA, Israel and TAMPA, Fla., Aug. 1, 2017 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients undergoing cardiac ...

TAMPA, Florida, March 10, 2020 /PRNewswire/ -- Keystone Heart Ltd., a Venus Medtech Company, today announced European CE Mark for the TriGUARD 3™ Cerebral Embolic Protection (CEP) Device. The device ...

CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...

A US Food and Drug Administration (FDA) advisory panel struggled to muster support for marketing clearance of the TriGuard 3 (Keystone Heart) device for use during transcatheter aortic valve ...

CHICAGO, IL—A range of new retrospective analyses and single-center series are building the case for cerebral embolic protection in TAVR procedures, hinting at relative reductions in stroke or death ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective capture of embolic debris and does not change neurocognitive function for ...